Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

Completed · Not applicable

Conditions studied: Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity, Heart Health Markers

In brief

BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints.

Key facts

Study ID
NCT06333496
Run by
Alpine Biotech LLC
People needed
12
Starts
2024-01-02
Expected to finish
2024-05-08
Last updated by the study team
2024-12-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.